Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.

Wuxi AppTec and Pfizer contributed to a series A round that will support progress of Simcha Therapeutics' immuno-oncology treatments toward clinical trials.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.

OneProjects, an irregular heartbeat imaging system developer assisted by two Irish universities, will use the cash to pursue commercialisation in the US.

The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.

Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.

Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.

Nestlé Health Science and Takeda participated in a series E round for Enterome, which received $52.6m in equity and debt financing through the deal.

Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.